Recombinant Host Cell Production of Cannabinoid Analogs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing cannabinoid compounds are inefficient and lack sustainable biopharmaceutical preparation methods, limiting their application in human therapeutic indications such as neurological conditions, mood/behavior disorders, infections, and cancers.
Innovation Solution
The development of new cannabinoid compounds and methods for their production using modified recombinant host cells that express specific polynucleotides to convert thioesters into cannabinoid analogs, enabling the production of pharmaceutical-grade cannabinoids through enzymatic and chemoenzymatic processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current methods for producing pharmaceutical-grade cannabinoids are used, then production can be achieved, but the methods are not sustainable and lack efficiency
Solution Approach 1:
The patent replaces traditional mechanical/chemical extraction and synthesis methods with a biological system (recombinant host cells) that uses enzymatic pathways to produce cannabinoids. This substitution of biological systems for mechanical/chemical processes enables sustainable production while maintaining high efficiency, as the biological system can continuously produce pharmaceutical-grade cannabinoids through controlled cellular metabolism rather than resource-intensive extraction or multi-step chemical synthesis
Solution Approach 2:
The patent modifies the biological parameters of host cells through genetic engineering to optimize cannabinoid production. By changing the genetic makeup and metabolic parameters of recombinant host cells, the system achieves high-yield production of pharmaceutical-grade cannabinoids with controlled purity and potency, resolving the contradiction between production efficiency and manufacturing sustainability
2Productivity
If traditional cannabinoid production methods are used, then cannabinoids can be obtained, but the therapeutic potential and production efficiency are limited
Solution Approach 1:
The patent divides the cannabinoid production process into distinct modular components: specific recombinant host cells engineered with particular enzymatic pathways, controlled culture conditions, and targeted metabolic routes. This segmentation allows for optimized production of specific cannabinoid analogs with consistent therapeutic properties, enhancing both production efficiency and the reliability of therapeutic outcomes through standardized, controlled synthesis
Solution Approach 2:
The patent creates a universal biopharmaceutical platform using recombinant host cells that can produce multiple different cannabinoid analogs by simply changing the genetic instructions or culture conditions. This multi-functional system maintains high production efficiency while providing reliable access to various therapeutic cannabinoids for different medical indications, resolving the contradiction between productivity and therapeutic reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the efficient and sustainable production of cannabinoid analogs with therapeutic potential, addressing a range of human health issues including neurological conditions, mood/behavior disorders, infections, and cancers.
Implementation Method 1
a first polynucleotide that encodes a synthase that converts the thioester according to Formula II and malonyl CoA to a tetraketide according to Formula III
Implementation Method 2
a second polynucleotide that encodes a 2-alkyl-4,6-dihydroxybenzoic acid cyclase that converts the tetraketide according to Formula III to the compound of Formula IV
Data Source
AI summary
Provided herein are cannabinoid analogs, including halogenated cannabinoid analogs, hydroxylated cannabinoid analogs, deuterated cannabinoid analogs, and tritiated cannabinoid analogs. The cannabinoid analogs can be prepared by partial or total expression in modified host cells, such as recombinantly modified yeast cells, optionally in combination with chemical synthetic steps.